Highlights TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
5.82 ^USD	+1.93%		-1.85%	-0.17%

Jul. 01	TScan Therapeutics, Inc.(NasdaqGM:TCRX) added to Russell Small Cap Comp Value Index	CI
Jul. 01	TScan Therapeutics, Inc.(NasdaqGM:TCRX) added to Russell Small Cap Completeness Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TScan Therapeutics' Potential Blood Cancer Therapies Receive FDA Regenerative Medicine Status	May. 29	MT
TScan Therapeutics Receives FDA?s Regenerative Medicine Advanced Therapy Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies	May. 29	CI
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Tscan Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Tcr-T Therapy for the Treatment of Solid Tumors	May. 09	CI
TScan Therapeutics Closes $150.1 Million Securities Offering	Apr. 19	MT
TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants	Apr. 17	MT
TScan Therapeutics Launches $125 Million Securities Offering; Shares Rise After Hours	Apr. 16	MT
TScan Therapeutics, Inc. Provides Clinical Pipeline Update and Highlights Near-Term Priorities	Apr. 16	CI
TScan Therapeutics Files $300 Million Mixed-Securities Shelf	Mar. 06	MT
TScan Therapeutics Q4 Net Loss Narrows, Revenue Increases	Mar. 06	MT
TScan Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Tscan Therapeutics, Inc. Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 At the 65Th American Society of Hematology Annual Meeting and Exposition	Dec. 09	CI
TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
TScan Therapeutics Says Investigational New Drug Application for Solid Tumor Treatment Received US FDA Clearance	23-06-06	MT
TScan Therapeutics, Inc. Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting	23-05-17	CI
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Amgen, TScan Therapeutics Partner to Identify Therapeutic Targets for Crohn's Disease Treatment	23-05-09	MT
Amgen and TScan Therapeutics Announces Collaboration to Identify Novel Targets in Crohn’s Disease	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Highlights

Filters